Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Gerdau controlling shareholder cuts preferred stake by BRL 2.18 million in market sale

Gerdau controlling shareholder cuts preferred stake by BRL 2.18 million in market sale

BitgetBitget2026/10/09 20:08

Gerdau disclosed cash sales of preferred shares by its majority shareholder, totaling R$ 2.18 million at an average price of 25.40760. Executives/management also reported a cash sale of preferred shares totaling R$ 1.36 million at an average price of 26.21320. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gerdau SA published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.

  • Gerdau disclosed cash sales of preferred shares by its majority shareholder, totaling R$ 2.18 million at an average price of 25.40760.
  • Executives/management also reported a cash sale of preferred shares totaling R$ 1.36 million at an average price of 26.21320.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gerdau SA published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21